Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008.
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies
Published in November 20th, 2008
Comments Off
Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer
Published in November 20th, 2008
Comments Off
Ortho Biotech Products, L.P. today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer (ROC).
Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
Published in November 20th, 2008
Comments Off
Bionovo, Inc. (NASDAQ:BNVI) announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology’s Fifth International Conference in Atlanta, Georgia.
FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
Published in November 20th, 2008
Comments Off
GlaxoSmithKline (NYSE:GSK) today announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA(R) (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
Published in November 20th, 2008
Comments Off
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, reported today that the FDA has accepted Vanda’s resubmission of the iloperidone New Drug Application (NDA).
Obama Picks Daschle for HHS Secretary
Published in November 20th, 2008
Posted by Medscape Pharmacists Headlines in Drugs and Food Information, Health Information, Pharmaceutical Industry News
Comments Off
By selecting former Senator Tom Daschle (D-SD) to head the Department of Health and Human Services, President-Elect Barack Obama has found a point person for sweeping healthcare reform who also shares his bipartisan read realistic approach to politics.
Medscape Medical News
Helicobacter pylori: Friend and Foe?
Published in November 20th, 2008
Posted by Medscape Pharmacists Headlines in Drugs and Food Information, Health Information, Pharmaceutical Industry News
Comments Off
How do we reach across the aisle? Paul Auwaerter, MD, MBA, discusses the tenuous nature of the important relationship with the H pylori pathogen in his video blog.
Medscape Infectious Diseases
FDA Acts to Avoid Shortage and Strengthen the Safety of Sucraid
Published in November 20th, 2008
Comments Off
The U.S. Food and Drug Administration today issued an expedited approval of a supplemental application that allows for changes in the manufacturing of Sucraid (sacrosidase) Oral Solution.
EPA seeks public comment on proposal to add hazardous pharmaceutical waste to universal waste rule
Published in November 20th, 2008
Comments Off
To help provide a streamlined system for disposing of hazardous pharmaceutical waste that is protective of public health and the environment, the U.S. Environmental Protection Agency is proposing to add hazardous pharmaceutical waste to the Universal Waste Rule.
FDA Approves New Drug to Treat Severe Form of Epilepsy
Published in November 20th, 2008
Comments Off
The U.S. Food and Drug Administration has approved a new drug, Banzel (rufinamide), for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome.